Zhu, Bangfu
Parsons, Tom
Foley, Christopher
Shaw, Yeng
Dunckley, Travis
Hulme, Christopher
Hodge, James J. L.
Funding for this research was provided by:
Alzheimer's Research UK (ARUK-IRG2019B-003)
Alzheimer’s Drug Discovery Foundation and National Institute of Aging (R01AG067926-01)
Biotechnology and Biological Sciences Research Council (BB/W000865/1)
Article History
Received: 9 November 2021
Accepted: 7 September 2022
First Online: 23 September 2022
Competing interests
: Patents encompassing DYR219 and DYR533 have been in-licensed by Iluminos Therapeutics, founded by the co-authors C.H. and T.D., apart from this potential competing interest these authors have no other competing interests. They did not fund, design, perform or write up any of the experiments performed in the study. B.Z., T.P., Y.S., C.F., and J.J.L.H. have no competing interests.